Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Wan

Showing results (501-510 of 526) with videos related to

Pageof 53
Sort By:
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
The Journal of Clinical Investigation|September 24, 2020
CMV viral load kinetics as surrogate endpoints after allogeneic transplantationElizabeth R Duke, Brian D Williamson, Bhavesh Borate, et al.
The Journal of Pathology|April 29, 2018
Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3η in oncocytomasJie Feng, Qi Zhang, Chuzhong Li, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
European Journal of Medicinal Chemistry|December 15, 2021
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancersPeng Zhao, Linghang Zhuang, Xiangzhu Wang, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2024
Large-scale genome sequencing of giant pandas improves the understanding of population structure and future conservation initiativesTianming Lan, Shangchen Yang, Haimeng Li, et al.
Pageof 53

Showing results (501-510 of 526) with videos related to

Sort By:
Pageof 53
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
The Journal of Clinical Investigation|September 24, 2020
CMV viral load kinetics as surrogate endpoints after allogeneic transplantationElizabeth R Duke, Brian D Williamson, Bhavesh Borate, et al.
The Journal of Pathology|April 29, 2018
Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3η in oncocytomasJie Feng, Qi Zhang, Chuzhong Li, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
European Journal of Medicinal Chemistry|December 15, 2021
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancersPeng Zhao, Linghang Zhuang, Xiangzhu Wang, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2024
Large-scale genome sequencing of giant pandas improves the understanding of population structure and future conservation initiativesTianming Lan, Shangchen Yang, Haimeng Li, et al.
Pageof 53